scispace - formally typeset
W

Woo Joo Kim

Researcher at Korea University

Publications -  286
Citations -  6890

Woo Joo Kim is an academic researcher from Korea University. The author has contributed to research in topics: Vaccination & Influenza vaccine. The author has an hindex of 35, co-authored 257 publications receiving 5352 citations. Previous affiliations of Woo Joo Kim include Yonsei University & Korea University Medical Center.

Papers
More filters
Journal ArticleDOI

Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.

TL;DR: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site.
Journal ArticleDOI

Effectiveness of the influenza vaccine at preventing hospitalization due to acute lower respiratory infection and exacerbation of chronic cardiopulmonary disease in Korea during 2010-2011.

TL;DR: Influenza vaccination reduced the rate of hospitalization among patients with underlying chronic heart disease, particularly those patients 65 years old and greater, particularly in patients aged 65 years and older.
Journal ArticleDOI

Viral shedding from diverse body fluids in a patient with severe fever with thrombocytopenia syndrome.

TL;DR: Results suggest that droplet transmission can occur through close contact with infected patients with severe fever with thrombocytopenia syndrome through human-to-human transmission.
Journal ArticleDOI

Regional outbreak of mumps due to genotype H in Korea in 1999.

TL;DR: This is the first study on the outbreak due to mumps virus genotype H and provides information to assess the understanding of recent outbreaks of mumps in Korea.
Journal ArticleDOI

Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.

TL;DR: PCV13 vaccination is more cost-effective in elderly subjects aged ≥ 65 years compared to the current PPSV23 vaccination strategy, and the cost-effectiveness of vaccination strategies need to be reassessed.